drugset / Trial / NCT00532844

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

NCT00532844

Phase 2 Completed 52 enrolled BioMarin Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This Phase 2, randomized, open-label, 2-treatment, 2-sequence, 2-period crossover, pharmacokinetic (PK) study will compare plasma concentrations of BH4 in subjects with endothelial dysfunction following 14 days of treatment by each of 2 regimens: sapropterin dihydrochloride with vitamin C and sapropterin dihydrochloride alone.

Timeline

Start
2007-09
Primary completion
2008-11
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 500 mg Oral
Subject sapropterin Unknown 5 mg/kg Oral

Indications

No indication recorded.